United States Patent 12,569,469 (Edaravone): What the Claims Cover and Where the Landscape Sits
United States Drug Patent US 12,569,469 claims an amyotrophic lateral sclerosis (ALS) treatment method using edaravone in a liquid pharmaceutical composition with meal-timing constraints designed to limit exposure loss versus fasting. The claim set tightens the dosing window by specifying time from meals to administration (with high-fat, low-fat, or caloric supplement examples) and a fixed post-dose interval to the next meal, plus optional constraints on edaravone concentration (2 mg/mL+), mixing/recency of preparation (within 3 hours), intragastric delivery via tube, and specific dose and schedule patterns.
1. What is the core claimed invention?
Claim 1: Meal-timing controlled liquid edaravone for ALS
Independent claim 1 recites:
- Use: “treating amyotrophic lateral sclerosis”
- Route: orally or intragastrically administering a liquid pharmaceutical composition comprising edaravone
- First time interval (meal-to-dose) with three alternative exemplars, each tied to a specific macronutrient/caloric condition:
- High-fat meal: 800 to 1000 calories, 50% fat, administered 8 hours before dosing
- Low-fat meal: 400 to 500 calories, 25% fat, administered 4 hours before dosing
- Caloric supplement: 250 calories, administered 2 hours before dosing
- Second time interval (dose-to-next-meal): the next meal occurs 1 hour after administration
- Exposure performance requirements versus fasting:
- Cmax decrease < 20% relative to Cmax in a fasting window of 10 hours or longer, and/or
- AUC decrease < 10% relative to AUC in a fasting window of 10 hours or longer
- Overall structure: meal timing is engineered to preserve edaravone exposure while allowing dosing to occur in proximity to subsequent feeding.
Dependent claims refine the same method
The dependent claims add narrower limitations tied to formulation properties, preparation steps, administration hardware, and regimen specifics.
2 mg/mL blending amount
- Claim 2: liquid composition contains edaravone at ≥ 2 mg/mL
Preparation by mixing dry particulate with aqueous solution
Claims 3 to 6 recite mixing dry particulate edaravone with water to form the liquid composition:
- Claim 3/4: mixing dry particulate with aqueous solution to prepare the liquid composition
- Claim 5/6: preparation is completed within 3 hours prior to administration
Intragastric delivery by tube
- Claim 7: intragastric administration
- Claims 8-9: via a tube:
- percutaneous endoscopic gastrostomy catheter (PEG)
- nasopharyngeal gastric catheter
Dose amount constraints
- Claim 10: 90 to 120 mg edaravone per administration
- Claim 11: once daily, 105 mg
- Claim 12: once daily, 100 mg
- Claim 13: once daily, 90 mg
Intermittent regimen cycling
- Claim 14: intermittent administration with a cycle having:
- an administration period and an interruption period
- repeated at least twice
- Claim 15: examples of cycles:
- initial cycle: 14 days on + 14 days off
- subsequent cycle: 10 administration days out of 14 days, plus 14 days interruption
Dry particulate form factor
- Claims 16-19: dry particulate edaravone is one of:
- tablet
- capsule
- powder
- fine granule
- granules
2. Claim scope translated into “design constraints”
From a freedom-to-operate and prosecution/validity lens, US 12,569,469 is less about “edavarone for ALS” (which is well established) and more about a delivery-and-food interaction regime for liquid edaravone.
A. Timing rules are the heart of the claim
The claim is structured around:
- First interval before administration tied to a meal type and its calorie/fat profile, with precise hours (8, 4, or 2)
- Second interval after dosing: 1 hour until the next meal
- Exposure gatekeeping: Cmax and/or AUC must not drop beyond specified thresholds versus fasting for 10+ hours
This makes the practical claim scope depend on:
- whether a competitor’s regimen can be characterized as meeting the specified meal-type timing examples, and
- whether their exposure data show <20% Cmax drop and/or <10% AUC drop compared to the fasting comparator.
B. “Liquid pharmaceutical composition” is a structural anchor
The claims require a liquid pharmaceutical composition of edaravone. They do not restrict to a particular excipient set in the provided claim text, but they do require:
- 2 mg/mL or more in claim 2 (optional but meaningful if asserted)
- and/or creation from dry particulate + aqueous solution (claims 3-6)
C. Preparation recency (within 3 hours) is an enforcement lever
If the accused process uses dry particulates but prepares the liquid substantially earlier than dosing, it may fall outside claims 5/6 (depending on how claim 3-4 are asserted). Conversely, maintaining a same-day mixing window aligns with at least one dependent claim.
D. Route and device constraints are optional but matter for design-around
Claims 7-9 narrow to intragastric administration via tube, including PEG and nasopharyngeal gastric catheter. If a competitor administers orally only (no tube), it weakens those claim paths.
E. Dose and regimen constraints narrow further
Claims 10-13 lock into 90/100/105 mg daily once dosing patterns or 90-120 mg per administration. Claims 14-15 specify intermittent cycles (e.g., 14-day on/14-day off; then 10 days out of 14) that align with existing ALS treatment cycling patterns.
3. What is “in” versus “out”: likely claim coverage boundaries
The provided claim set suggests the following coverage logic:
Likely “in”
- ALS patients receiving edaravone as a liquid, by oral or intragastric means
- Dosing scheduled relative to meals in a way that matches one of the three meal exemplars:
- high-fat (800-1000 cal, 50% fat) → dose at 8 hours
- low-fat (400-500 cal, 25% fat) → dose at 4 hours
- 250-cal supplement → dose at 2 hours
- Next meal at 1 hour after dose
- Exposure results meeting the performance gates:
- Cmax decrease <20% vs fasting 10+ hours, and/or
- AUC decrease <10% vs fasting 10+ hours
Likely “out”
- Liquid edaravone dosing with meal timing that does not meet the claimed time-at-dose structure (8/4/2 hours tied to the specified meal profiles, and 1 hour to next meal)
- Regimens that accept larger Cmax/AUC losses versus fasting beyond the stated thresholds
- Dry formulation administered without forming a liquid composition (unless infringement theory is broadened, which is not shown in the provided claim text)
- Intragastric-tube-specific embodiments if a competitor uses non-tube oral administration
4. Patent landscape: where this sits relative to “meal effect” and edaravone fundamentals
High-level positioning
- The claim set is built around edavarone exposure preservation during feeding. The landscape issue is not “ALS indication” but rather:
- oral/intragastric formulation format
- liquid composition
- food timing control
- exposure retention metrics (Cmax/AUC gates)
- The presence of PEG and nasopharyngeal gastric catheter language suggests the patent also targets real-world feeding tube workflows where meal timing varies.
How competitors will likely map risk
Competitors in edaravone reformulation or administration typically fall into two buckets:
- Existing edaravone regimens (e.g., established dosing schedules and conventional administration timing) that may not provide the claimed food-interval structure and exposure thresholds
- Food-effect mitigation strategies (timing, formulation adjustments, or prodrug approaches) aimed at reducing food-driven exposure loss
US 12,569,469 primarily captures strategies in bucket (2) if they land on:
- the claimed liquid mode,
- the claimed meal-to-dose and dose-to-next-meal intervals, and
- the claimed Cmax/AUC performance thresholds.
Practical enforcement theme
If asserted, the patent gives the patentee multiple ways to frame infringement:
- process-based (mixing within 3 hours; dry particulate + aqueous solution)
- use-based (ALS treatment with timing schedule)
- performance-based (Cmax/AUC relative to fasting)
Performance gates can become evidentiary battlegrounds in claim construction and infringement analysis because they depend on pharmacokinetic comparisons.
5. Claim-by-claim breakdown for freedom-to-operate screening
Independent claim
- Claim 1: method of treating ALS with liquid edaravone under specific first and second time intervals, with Cmax and/or AUC drop limits versus fasting 10+ hours.
Dependent claim set
| Claim |
Additional limiter |
Design implication for challengers |
| 2 |
edaravone concentration ≥ 2 mg/mL |
Formulation strength and concentration control becomes relevant |
| 3 |
mixing dry particulate edaravone + aqueous solution |
Process must include this preparation pathway |
| 4 |
same concept as 3 (wording variant in provided text) |
Same effect; both versions narrow process steps |
| 5 |
preparation completed within 3 hours prior to dosing |
Same-day mixing window can drive infringement/non-infringement |
| 6 |
same concept as 5 (wording variant) |
Same-day timing is an important fork |
| 7 |
intragastric administration |
Tube vs oral distinctions matter |
| 8 |
intragastric via tube |
Adds device pathway |
| 9 |
tube is PEG or nasopharyngeal gastric catheter |
Specific device list can narrow asserted scope |
| 10 |
dose 90-120 mg per administration |
Dose range alignment is important |
| 11 |
once daily 105 mg |
Specific regimen alignment |
| 12 |
once daily 100 mg |
Specific regimen alignment |
| 13 |
once daily 90 mg |
Specific regimen alignment |
| 14 |
intermittent cycles (administration + interruption) repeated at least twice |
Regimen structure must match |
| 15 |
initial 14 on/14 off, later 10/14 on within 14-day interruption framework |
Strong schedule mapping |
| 16-19 |
dry particulate form: tablet/capsule/powder/granules |
Physical form can matter if process differs |
6. How to analyze infringement risk for a hypothetical entrant (using only the stated claim text)
Even without knowing a specific competitor’s product, the claim structure implies a simple risk matrix:
- Product format
- If competitor does not market a liquid edaravone: risk drops against claim 1 (unless doctrine of equivalents is used, not evaluated here).
- Food timing regimen
- The competitor must be able to show its dosing is 8 hours after high-fat (800-1000 cal, 50% fat) or 4 hours after low-fat (400-500 cal, 25% fat) or 2 hours after 250-cal supplement, with the next meal 1 hour after dosing.
- Exposure outcome
- The competitor’s PK must demonstrate <20% Cmax and/or <10% AUC decrease vs fasting 10+ hours.
- Process and preparation (if claims 3-6 are asserted)
- Dry particulates + aqueous mixing, with preparation completion within 3 hours.
- Administration route and device (if claims 7-9 are asserted)
- Intragastric via PEG or nasopharyngeal gastric catheter.
- Dose and regimen (if claims 10-15 are asserted)
- Dose of 90/100/105 mg once daily, or 90-120 mg, and cycles aligned to the intermittent pattern.
This is a “claim-to-variables” map aligned to how patents like this are typically litigated: formulation type, timing schedule, and PK performance are the main vectors.
7. Key takeaways
- US 12,569,469 is a meal-timing optimized liquid edaravone method for ALS, centered on preserving exposure (Cmax/AUC) under feeding conditions through a specific dosing schedule relative to meals and the next meal.
- The scope is not generic “edaravone in ALS.” It is tightly framed by:
- 8/4/2 hour first intervals tied to high-fat/low-fat/caloric supplement exemplars,
- 1 hour second interval to next meal,
- and PK gates of Cmax <20% or AUC <10% loss versus fasting ≥10 hours.
- Dependent claims add enforcement hooks around:
- ≥2 mg/mL edaravone concentration,
- dry particulate + aqueous mixing with <3 hour recency,
- tube-based intragastric delivery (PEG or nasopharyngeal gastric catheter),
- specific daily dosing amounts and intermittent on/off cycles.
FAQs
1. What is the single most important limiting feature in US 12,569,469?
Claim 1’s meal-to-dose timing plus PK performance thresholds: the dosing windows (8/4/2 hours to administration depending on meal condition, and 1 hour to the next meal) paired with Cmax/AUC loss limits versus fasting.
2. Does the patent claim a specific edaravone formulation composition beyond “liquid”?
The provided claims specify liquid pharmaceutical composition and, in dependent claim 2, require edaravone ≥2 mg/mL. The claim text also includes process constraints (dry particulate + aqueous mixing; preparation within 3 hours) rather than listing a full excipient recipe.
3. Are dosing schedules like “once daily 100 mg” covered?
Yes. Claims 11-13 specify once-daily dosing at 105 mg, 100 mg, and 90 mg.
4. Does the patent cover feeding-tube administration?
Yes. Claims 7-9 include intragastric administration via a tube, specifically PEG or a nasopharyngeal gastric catheter.
5. What are the preparation timing constraints?
For the mixing pathway, claims 5-6 limit preparation completion to within 3 hours prior to administration.
References (APA)
[1] United States Patent No. 12,569,469. (n.d.). Method of treating amyotrophic lateral sclerosis using edaravone liquid composition with meal-timing intervals. United States Patent and Trademark Office.
